We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics... read more Featured Products: More products

Download Mobile App




Noninvasive Test Identifies Childhood Metabolic Disease Risk

By LabMedica International staff writers
Posted on 25 Jun 2014
Salivary biomarkers have been used as a tool for identifying children who are at risk for developing Type 2 diabetes (T2D).

The study of obesity-related metabolic syndrome or T2D in children is particularly difficult because of fear of needles; however a noninvasive approach to study inflammatory parameters in an at-risk population of children may provide proof-of-principle for future investigations of vulnerable subjects.

Scientists from the Forsyth Research Institute, Cambridge, MA, USA) working with colleague in Kuwait, evaluated metabolic differences in 744, 11-year old children selected from underweight, normal healthy weight, overweight and obese categories by analyzing fasting saliva samples for 20 biomarkers. More...
Saliva supernatants were obtained following centrifugation and used for analyses.

All assays on the 744 saliva samples for the 20 biomarkers were performed on saliva supernatant using four multiplex magnetic bead panels on a Luminex 100 platform (Luminex, Austin, TX, USA). A subset of 213 saliva supernatants (approximately 54 from each body weight category) were randomly selected and assayed for total protein. The assay was performed using the commercial kit Pierce 660 nm protein assay, (Pierce Biotechnology Rockford, IL, USA) which has a working range of 50 to 2,000 µg/ml. Protein values were determined on saliva supernatant samples using bovine serum albumin as a standard implemented on a robotic chemical analysis unit, the EVO 100 with a Sunrise spectrophotometer set at 660 nm, (Tecan US; Morrisville NC, USA).

Salivary C-reactive protein (CRP) was six times higher, salivary insulin and leptin were three times higher, and adiponectin was 30% lower in obese children compared to healthy normal weight children. Categorical analysis suggested that there might be three types of obesity in children. Distinctly inflammatory characteristics appeared in 76% of obese children while in 13%, salivary insulin was high but not associated with inflammatory mediators. The remaining 11% of obese children had high insulin and reduced adiponectin. In the non-obese children 40% were found in groups which, based on biomarker characteristics, may be at risk for becoming obese.

The authors concluded that they had identified four salivary biomarkers in their study subjects that change significantly with increasing obesity; insulin, CRP, adiponectin, and leptin. The results of this study suggest that obesity may be characterized and classified by salivary biomarker concentrations. The use of these relatively noninvasive markers, particularly in longitudinal studies, to investigate the development of metabolic diseases in children and to evaluate therapeutic interventions, could be used to develop prevention strategies. The study was published on June 10, 2014, in the journal Public Library of Science ONE.

Related Links:

Forsyth Research Institute
Luminex
Pierce Biotechnology 



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.